Dingshan Biotechnology

Dingshan Biotechnology is a clinical-stage biopharmaceutical company headquartered in Guangzhou, China, dedicated to the discovery and development of innovative small molecule therapeutics. The company primarily focuses on the fields of immunology and oncology, leveraging its expertise in kinase inhibition to target validated pathways such as TYK2 and HPK1. Its lead clinical candidate, DS-7011, is a selective TYK2 inhibitor currently undergoing clinical evaluation for the treatment of autoimmune conditions like psoriasis. Founded by industry veterans with significant experience at global pharmaceutical firms, Dingshan Biotechnology aims to deliver high-quality, differentiated medicines to patients with significant unmet medical needs. The company is backed by prominent venture capital firms and maintains research and development facilities within the Guangzhou International Bio Island.